Английская Википедия:Benralizumab
Шаблон:Short description Шаблон:Drugbox
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.[1][2]
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[3][4] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[5] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[6]
Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[7]
References
External links
Шаблон:Monoclonals for immune system Шаблон:Interleukin receptor modulators Шаблон:AstraZeneca Шаблон:Portal bar
Шаблон:Monoclonal-antibody-stub
Шаблон:Respiratory-system-drug-stub
развернутьПартнерские ресурсы |
---|
- ↑ Statement on a Nonproprietary Name Шаблон:Webarchive adopted by the USAN Council: Benralizumab
- ↑ Шаблон:Cite journal
- ↑ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite web
- ↑ Шаблон:Drugs.com